Tracks tenecteplase use for stroke given after 4.5 hours
Observes tenecteplase given to adults with acute ischemic stroke after 4.5 hours.
Plain-language title generated from the registry record
Registry title: Extended Time Window Intravenous Tenecteplase Thrombolysis Registry for Acute Ischemic Stroke
Key facts
- Where
- Guangzhou and Guankou, ChinaSee the 2 sites
Where in China
- Sun Yat-sen Memorial Hospital, Sun Yat-sen UniversityGuangzhou, ChinaNo longer taking part
- Liuyang Jili HospitalGuankou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Trial code
- NCT07536165
- Record updated
- 17 April 2026
- Original description
The EXTEND-TNK Registry is a prospective, multicenter, observational cohort study designed to evaluate the effectiveness and safety of intravenous tenecteplase administered beyond 4.5 hours after last known well in patients with acute ischemic stroke (AIS) in routine clinical practice across China.Read full original descriptionShow less
Extended Time Window Intravenous Tenecteplase Thrombolysis Registry for Acute Ischemic Stroke (EXTEND-TNK Registry)
The EXTEND-TNK Registry is a prospective, multicenter, observational cohort study designed to evaluate the effectiveness and safety of intravenous tenecteplase administered beyond 4.5 hours after last known well in patients with acute ischemic stroke (AIS) in routine clinical practice across China.
Inclusion: 1. Age ≥ 18 years; 2. Clinical diagnosed of acute ischemic stroke; 3. Time from last known well (LKW) to initiation of intravenous thrombolysis > 4.5 hours (including wake-up stroke and unwitnessed stroke); 4. Received intravenous tenecteplase; 5. Provided written informed consent.
Exclusion: 1. Any condition judged by the investigator to make the participant unsuitable for study participation or follow-up (e.g., psychiatric disorders, cognitive impairment, or emotional disturbances).